The Company is guided by the humanitarian and people-centric spirit of benefiting the public through superior products. Simultaneously, we prioritize and safeguard shareholder rights and interests.
Our ultimate governing body is formed by highly qualified individuals elected through the Shareholders' Meeting. Furthermore, the Board of Directors comprises experts who possess extensive practical experience across commerce, finance, accounting, and the biotech/healthcare industry, ensuring the Board effectively executes all requisite capabilities based on their diverse professional backgrounds.
To navigate the rapidly evolving market landscape and to establish a more robust corporate governance framework, the Board of Directors consists of seven (7) seats, including three (3) Independent Directors.
These Independent Directors are tasked with assisting the Board in fulfilling its responsibilities. Furthermore, the Board has authorized the establishment of the Compensation Committee and the Audit Committee under its authority, thereby strengthening the oversight of the Company’s operational governance and enhancing the protection of shareholder interests.
Current Term of Office: June 30, 2025 – June 29, 2028.
Chairperson
Ho-Ming Investment Co., Ltd
Representative:
Director:
Weikai International Limited
Representative:
Director
Director:
Jing Hong Capital Co., Ltd
Representative:
Independent Directors
Independent Directors
Independent Directors
The Company's Board of Directors consists of seven directors with different professional backgrounds, including three Independent Directors and four non-independent directors, and directors who do not have the status of managerial officers of the Company account for more than half of the Board seats Members of the Company's 6th Term Board of Directors: one current director is aged between 41 and 50, and six are aged 51 or above Currently, there is one female Director. The Company will continue to pay attention to outstanding female Director candidates with professional qualifications, and plans to nominate additional female Director candidates at the 2028 Annual General Meeting reelection, in order to gradually achieve the goal that Directors of either gender account for one-third of the Board seats; all members possess operational judgment, accounting and financial analysis, business management, crisis management, industry knowledge, international market perspective and leadership and decision-making capabilities, and the three Independent Directors have professional backgrounds in law, accounting and finance, respectively.
Since 2022, three Independent Directors have been established, accounting for 43%, and the three Independent Directors are serving a second term and have tenure of less than four years.
The specific management objectives and achievement status of the Company’s diversity policy are as follows:
